These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 37762442)
1. Exploring the Syndecan-Mediated Cellular Internalization of the SARS-CoV-2 Omicron Variant. Letoha A; Hudák A; Letoha T Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762442 [TBL] [Abstract][Full Text] [Related]
2. Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variant's Superior Transmission. Hudák A; Veres G; Letoha A; Szilák L; Letoha T Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054983 [TBL] [Abstract][Full Text] [Related]
3. Mutual Inhibition of Antithrombin III and SARS-CoV-2 Cellular Attachment to Syndecans: Implications for COVID-19 Treatment and Vaccination. Hudák A; Pusztai D; Letoha A; Letoha T Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062776 [TBL] [Abstract][Full Text] [Related]
4. Biodistribution and Cellular Internalization of Inactivated SARS-CoV-2 in Wild-Type Mice. Hudák A; Morgan G; Bacovsky J; Patai R; Polgár TF; Letoha A; Pettko-Szandtner A; Vizler C; Szilák L; Letoha T Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886958 [TBL] [Abstract][Full Text] [Related]
5. Contribution of Syndecans to the Cellular Entry of SARS-CoV-2. Hudák A; Letoha A; Szilák L; Letoha T Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069441 [TBL] [Abstract][Full Text] [Related]
6. Syndecan-4 Mediates the Cellular Entry of Adeno-Associated Virus 9. Hudák A; Roach M; Pusztai D; Pettkó-Szandtner A; Letoha A; Szilák L; Azzouz M; Letoha T Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834552 [TBL] [Abstract][Full Text] [Related]
7. Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions. Kwon PS; Xu S; Oh H; Kwon SJ; Rodrigues AL; Feroz M; Fraser K; He P; Zhang F; Hong JJ; Linhardt RJ; Dordick JS Commun Biol; 2023 Apr; 6(1):387. PubMed ID: 37031303 [TBL] [Abstract][Full Text] [Related]
8. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1. Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765 [TBL] [Abstract][Full Text] [Related]
11. Heparan Sulfate Proteoglycans in Viral Infection and Treatment: A Special Focus on SARS-CoV-2. De Pasquale V; Quiccione MS; Tafuri S; Avallone L; Pavone LM Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207476 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx. Kim SH; Kearns FL; Rosenfeld MA; Votapka L; Casalino L; Papanikolas M; Amaro RE; Freeman R Cell Rep Phys Sci; 2023 Apr; 4(4):101346. PubMed ID: 37077408 [TBL] [Abstract][Full Text] [Related]
13. Interactions between heparin and SARS-CoV-2 spike glycoprotein RBD from omicron and other variants. Gelbach AL; Zhang F; Kwon SJ; Bates JT; Farmer AP; Dordick JS; Wang C; Linhardt RJ Front Mol Biosci; 2022; 9():912887. PubMed ID: 36046608 [TBL] [Abstract][Full Text] [Related]
14. Heparan sulfate chains with antimitogenic properties arise from mesangial cell-surface proteoglycans. Wang A; Miralem T; Templeton DM Metabolism; 1999 Oct; 48(10):1220-9. PubMed ID: 10535382 [TBL] [Abstract][Full Text] [Related]
15. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. Kumar S; Karuppanan K; Subramaniam G J Med Virol; 2022 Oct; 94(10):4780-4791. PubMed ID: 35680610 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact. Abduljaleel Z; Melebari S; Athar M; Dehlawi S; Udhaya Kumar S; Aziz SA; Dannoun AI; Malik SM; Thasleem J; George Priya Doss C Cell Signal; 2023 Sep; 109():110798. PubMed ID: 37423342 [TBL] [Abstract][Full Text] [Related]
17. Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq. Rashid PMA; Salih GF Mol Biol Rep; 2022 Aug; 49(8):7437-7445. PubMed ID: 35698014 [TBL] [Abstract][Full Text] [Related]
18. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2. Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310 [TBL] [Abstract][Full Text] [Related]
19. PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding. Vanderlinden E; Boonen A; Noppen S; Schoofs G; Imbrechts M; Geukens N; Snoeck R; Stevaert A; Naesens L; Andrei G; Schols D Antiviral Res; 2023 Sep; 217():105700. PubMed ID: 37562608 [TBL] [Abstract][Full Text] [Related]
20. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]